scholarly journals How Medically Favorable Is the Replacement of the Invasive Colonoscopy With Cologuard Non-Invasive Colorectal Cancer Screening?

2021 ◽  
Vol 10 (1) ◽  
Author(s):  
Markella Bibidakis ◽  
Patricia Talarczyk
Keyword(s):  
Colorectal Cancer ◽  
Cancer Diagnosis ◽  
Goodness Of Fit ◽  
True Positive ◽  
Chi Square ◽  
Non Invasive ◽  
The Third ◽  
Common Cancer ◽  
The World ◽  
Medical Health

In 2014, the FDA approved the non-invasive and economical Cologuard test for colorectal cancer diagnosis for people reaching the age of 50, a milestone previously met with the “gold standard” of colorectal cancer diagnosis: the colonoscopy. Though prevention and treatment for the third most common cancer in the world have been heavily researched, the diagnosis has been thought to be set with the colonoscopy, without much room for modifications. To assess the possibility of replacing the invasive and costly colonoscopy with Cologuard screening as the first step in colorectal cancer diagnosis, a retrospective cohort study was done with data collected from a medical health record database of a northeast Ohio hospital. Medical record numbers were matched with age, sex, any personal or family history, and the results of the colonoscopies of 111 patients with positive Cologuard tests. Of the 111 patients, 92 proceeded with the colonoscopy. The sensitivities, or true-positive rates of results, were calculated for groups organized with respect to age, sex, and previous family and personal oncologic history. Since the data is categorical, a goodness of fit chi-square was done for the statistical analysis, resulting in a failure to reject the null hypothesis with χ2=0.09318 and p=6.571. In conclusion, the replacement of the invasive colonoscopy with Cologuard non-invasive screening as the first step in colorectal cancer diagnosis could not be proven statistically significant and, therefore, medically favorable.

scholarly journals Linking Obesity with Colorectal Cancer: Epidemiology and Mechanistic Insights

Cancers ◽  
2020 ◽  
Vol 12 (6) ◽  
pp. 1408 ◽  
Author(s):  
Pengfei Ye ◽  
Yue Xi ◽  
Zhiying Huang ◽  
Pengfei Xu
Keyword(s):  
Colorectal Cancer ◽  
Molecular Mechanisms ◽  
The United States ◽  
Cancer Epidemiology ◽  
Medical Needs ◽  
The Third ◽  
Common Cancer ◽  
The World ◽  
Treatment Of Obesity ◽  
Unmet Medical Needs

The incidence of obesity and colorectal cancer (CRC) has risen rapidly in recent decades. More than 650 million obese and 2 billion overweight individuals are currently living in the world. CRC is the third most common cancer. Obesity is regarded as one of the key environmental risk factors for the pathogenesis of CRC. In the present review, we mainly focus on the epidemiology of obesity and CRC in the world, the United States, and China. We also summarize the molecular mechanisms linking obesity to CRC in different aspects, including nutriology, adipokines and hormones, inflammation, gut microbiota, and bile acids. The unmet medical needs for obesity-related CRC are still remarkable. Understanding the molecular basis of these associations will help develop novel therapeutic targets and approaches for the treatment of obesity-related CRC.

scholarly journals Single Nucleotide Polymorphism in SMAD7 and CHI3L1 and Colorectal Cancer Risk

2018 ◽  
Vol 2018 ◽  
pp. 1-23 ◽  
Author(s):  
Amal Ahmed Abd El-Fattah ◽  
Nermin Abdel Hamid Sadik ◽  
Olfat Gamil Shaker ◽  
Amal Mohamed Kamal
Keyword(s):  
Colorectal Cancer ◽  
Genetic Variation ◽  
Sequence Variation ◽  
Regulatory Protein ◽  
Nucleotide Polymorphisms ◽  
Nucleotide Polymorphism ◽  
Single Nucleotide ◽  
The Third ◽  
Common Cancer ◽  
Cancer Initiation

Colorectal cancer (CRC) is one of the leading cancers throughout the world. It represents the third most common cancer and the fourth in mortality. Most of CRC are sporadic, arise with no known high-penetrant genetic variation and with no previous family history. The etiology of sporadic CRC is considered to be multifactorial and arises from the interaction of genetic variants of low-penetrant genes and environmental risk factors. The most common well-studied genetic variation is single nucleotide polymorphisms (SNPs). SNP arises as a point mutation. If the frequency of the sequence variation reaches 1% or more in the population, it is referred to as polymorphism, but if it is lower than 1%, the allele is typically considered as a mutation. Lots of SNPs have been associated with CRC development and progression, for example, genes of TGF-β1 and CHI3L1 pathways. TGF-β1 is a pleiotropic cytokine with a dual role in cancer development and progression. TGF-β1 mediates its actions through canonical and noncanonical pathways. The most important negative regulatory protein for TGF-β1 activity is termed SMAD7. The production of TGF-βcan be controlled by another protein called YKL-40. YKL-40 is a glycoprotein with an important role in cancer initiation and metastasis. YKL-40 is encoded by the CHI3L1 gene. The aim of the present review is to give a brief introduction of CRC, SNP, and examples of some SNPs that have been documented to be associated with CRC. We also discuss two important signaling pathways TGF-β1 and CHI3L1 that influence the incidence and progression of CRC.

scholarly journals Profile of Colorectal Tumor in Gastroentero-Hepatology Center, Department of Internal Medicine, Dr Soetomo Hospital, Surabaya

2020 ◽  
Vol 56 (1) ◽  
pp. 15
Author(s):  
Husin Thamrin ◽  
Khafidhotul Ilmiah ◽  
Ni Wajan Tirthaningsih
Keyword(s):  
Colorectal Cancer ◽  
Medical Records ◽  
Colorectal Tumor ◽  
Age And Gender ◽  
Male And Female ◽  
The Third ◽  
Common Cancer ◽  
Significant Difference ◽  
And Gender ◽  
Ethical Clearance

Colorectal cancer has became burden in the world.The latest study shows that colorectal cancer is the third most common cancer in men and second most common cancer in women globally. There are difference characteristic of epidemiology in every countries. Moreover, there is no study that represents epidemiology of colorectal cancer in Indonesia yet, especially in East Java. The aim of this study was to describe colorectal tumor profile by age and gender in Gastroentero-Hepatology Center, Dr Soetomo Hospital. This study has received a certificate of Ethical Clearance No.273/Panke.KKE/IV/2015, a descriptive retrospective study. We collected data using medical records, and patients who have been colonoscopy examination and suspected colorectal tumor were included. There were 201 patients, divided to 100 males and 101 females. The peak of incidence was on 51-60 years old group, but on the 31-40 years old incidence of colorectal tumor was increased. The youngest patient was 17 years old. And tumors are more likely develop in distal area, especially in rectum. This study shows a different characteristic profile of colorectal tumor, where tumor is developed at young people and there is no significant difference between male and female for the incidence.

scholarly journals A Complicated Colorectal Cancer Recurrence

2020 ◽  
Vol 18 (1) ◽  
pp. 25-27
Author(s):  
Anna Marija Lescinska ◽  
Valerija Grakova ◽  
Aleksandrs Malasonoks ◽  
Armands Sivins
Keyword(s):  
Colorectal Cancer ◽  
Case Report ◽  
Cancer Recurrence ◽  
Cancer Death ◽  
Treatment Results ◽  
Western Countries ◽  
The Third ◽  
Common Cancer ◽  
One Step ◽  
Colorectal Cancer Recurrence

SummaryThe case report demonstrates painstaking, one step at a time multitherapy for the third most common cancer and the third cause of cancer death in western countries – colorectal cancer. Multitherapeutic approach at specialized centers for the treatment of colorectal cancer is the cornerstone for reaching favorable treatment results and prognosis.

scholarly journals MicroRNAs and Apoptosis in Colorectal Cancer

2020 ◽  
Vol 21 (15) ◽  
pp. 5353 ◽  
Author(s):  
Hsiuying Wang
Keyword(s):  
Colorectal Cancer ◽  
Treatment Resistance ◽  
Therapeutic Resistance ◽  
Cancer Therapies ◽  
Malignant Cells ◽  
Apoptosis Induction ◽  
The Third ◽  
Anti Cancer ◽  
The World

Colorectal cancer (CRC) is the third leading cause of cancer death in the world, and its incidence is rising in developing countries. Treatment with 5-Fluorouracil (5-FU) is known to improve survival in CRC patients. Most anti-cancer therapies trigger apoptosis induction to eliminate malignant cells. However, de-regulated apoptotic signaling allows cancer cells to escape this signaling, leading to therapeutic resistance. Treatment resistance is a major challenge in the development of effective therapies. The microRNAs (miRNAs) play important roles in CRC treatment resistance and CRC progression and apoptosis. This review discusses the role of miRNAs in contributing to the promotion or inhibition of apoptosis in CRC and the role of miRNAs in modulating treatment resistance in CRC cells.

scholarly journals Molecular and Translational Research on Colorectal Cancer

2020 ◽  
Vol 21 (11) ◽  
pp. 4105
Author(s):  
Alessandro Passardi ◽  
Emanuela Scarpi ◽  
Paola Ulivi
Keyword(s):  
Colorectal Cancer ◽  
Translational Research ◽  
The Third ◽  
The World

Colorectal cancer (CRC) is the third most frequently diagnosed cancer in the world [...]

scholarly journals Non-Invasive Biomarkers for Early Detection of Breast Cancer

Cancers ◽  
2020 ◽  
Vol 12 (10) ◽  
pp. 2767
Author(s):  
Jiawei Li ◽  
Xin Guan ◽  
Zhimin Fan ◽  
Lai-Ming Ching ◽  
Yan Li ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Diagnosis ◽  
Early Stage ◽  
False Negative ◽  
Breast Cancer Diagnosis ◽  
Diagnostic Biomarkers ◽  
Circulating Micrornas ◽  
Non Invasive ◽  
Common Cancer ◽  
Volatile Organic

Breast cancer is the most common cancer in women worldwide. Accurate early diagnosis of breast cancer is critical in the management of the disease. Although mammogram screening has been widely used for breast cancer screening, high false-positive and false-negative rates and radiation from mammography have always been a concern. Over the last 20 years, the emergence of “omics” strategies has resulted in significant advances in the search for non-invasive biomarkers for breast cancer diagnosis at an early stage. Circulating carcinoma antigens, circulating tumor cells, circulating cell-free tumor nucleic acids (DNA or RNA), circulating microRNAs, and circulating extracellular vesicles in the peripheral blood, nipple aspirate fluid, sweat, urine, and tears, as well as volatile organic compounds in the breath, have emerged as potential non-invasive diagnostic biomarkers to supplement current clinical approaches to earlier detection of breast cancer. In this review, we summarize the current progress of research in these areas.

scholarly journals HUMAN DNA QUANTIFICATION IN THE STOOLS OF PATIENTS WITH COLORECTAL CANCER

2015 ◽  
Vol 52 (4) ◽  
pp. 293-298 ◽  
Author(s):  
Yolanda TEIXEIRA ◽  
Jacqueline Miranda LIMA ◽  
Maria Luiza Almeida Prado Oliveira SOUZA ◽  
Pedro AGUIAR Jr ◽  
Tiago Donizetti SILVA ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Roc Curve ◽  
Dna Quantification ◽  
Non Invasive ◽  
Human Dna ◽  
The World ◽  
Invasive Method ◽  
Colorectal Cancer Patients

Background - Colorectal cancer is one of the main cause of cancer in the world. Colonoscopy is the best screen method, however the compliance is less than 50%. Quantification of human DNA (hDNA) in the feces may be a possible screen non-invasive method that is a consequence of the high proliferation and exfoliation of cancer cells. Objective - To quantify the human DNA in the stools of patients with colorectal cancer or polyps. Methods - Fifty patients with CRC, 26 polyps and 53 with normal colonoscopy were included. Total and human DNA were analyzed from the frozen stools. Results - An increased concentration of hDNA in the stools was observed in colorectal cancer patients compared to controls and polyps. Tumors localized in the left side of the colon had higher concentrations of hDNA. There were no difference between polyps and controls. A cut off of 0.87 ng/mL of human DNA was determined for colorectal cancer patients by the ROC curve, with a sensitivity of 66% and a specificity of 86.8%. For polyps the cut off was 0.41, the sensitivity was 41% and the specificity 77.4%. Conclusion - A higher concentration of hDNA had been found in colorectal cancer patients The quantification of hDNA from the stools can be a trial method for the diagnosis of colorectal cancer.

scholarly journals Aflibercept in the Treatment of Metastatic Colorectal Cancer

2012 ◽  
Vol 6 ◽  
pp. CMO.S7432 ◽  
Author(s):  
Tzu-Fei Wang ◽  
Albert Craig Lockhart
Keyword(s):  
Colorectal Cancer ◽  
Metastatic Colorectal Cancer ◽  
Progression Free Survival ◽  
Phase Iii ◽  
Phase Iii Trial ◽  
Free Survival ◽  
The Third ◽  
Common Cancer ◽  
The Us

Colorectal cancer is the third most common cancer in the US. In recent decades, an improved understanding of the role of the angiogenesis pathway in colorectal cancer has led to advancements in treatment. Bevacizumab has been shown to improve the progression-free survival and overall survival when combined with cytotoxic chemotherapy in patients with metastatic colorectal cancer, and at present is the only antiangiogenesis agent approved for the treatment of this cancer. Aflibercept is a novel angiogenesis-targeting agent, and has demonstrated efficacy in treating metastatic colorectal cancer in a recent randomized Phase III trial. Here we review the role of angiogenesis in the tumorigenesis of colorectal cancer, strategies for targeting angiogenesis, and the clinical development of aflibercept.

scholarly journals PENGARUH USIA DAN JENIS KELAMIN PADA KEPATUHAN PASIEN DIABETES MELITUS MENGGUNAKAN OBAT ANTIDIABETES DI PERUM KETAPANG SOKARAJA KULON

2019 ◽  
Vol 10 (2) ◽  
pp. 76-81
Author(s):  
Ikhwan Yuda Kusuma
Keyword(s):  
Drug Information ◽  
Third Place ◽  
Chi Square ◽  
The Third ◽  
Central Java ◽  
The World ◽  
Chi Square Test ◽  
Survey Results ◽  
Central Java Province ◽  
Diabetes Melitus

ABSTRACT The WHO survey results show that the number of DM patients in Indonesia is ranked the 4th largest in the world. DM causes death by 5% every year. Deaths from DM are expected to increase by 50% in the next ten years. The results of the 2007 Central Java RISKESDAS showed that the prevalence of DM in Central Java province was 0.8% and overall was 1.3%. The highest prevalence is found in Cilacap Regency (3.9%), second place is Tegal City Regency (3.1%), for the third place is Surakarta (2.8%), fourth place is Pemalang (2.1%), and fifth place is occupied by Banyumas (1.9%) (Ministry of Health, 2009). This study used an experimental design by treating the group of cases. The research instruments in this study were interview guides about the number of remaining antidiabetic drugs to check the compliance and MMAS questionnaires that had been validated and translated into Indonesian versions (Setyaningsih, 2013). The results of data analysis using the Chi-Square test were obtained p = 0.220 (p> 0.05) based on the MMAS questionnaire, this indicates that this indicates that this study of age has a significant influence on the adherence of antidiabetic use in DM patients in Perum Ketapang Sokaraja Kulon.   Keywords: Age, Diabetes Mellitus, Drug Information          

Sign in / Sign up

Export Citation Format

Share Document